Zydus receives final approval for Pyridostigmine Bromide Tablets

Zydus receives market authorisation for Morphine Sulfate ER Tablets Ahmedabad, 1 July 2015 The Zydus group has received the market authorisation from the USFDA to market Morphine Sulfate ER Tablets. The product used in the treatment of chronic pain or cancer related pain will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St. Louis, USA. A subsidiary of Zydus Pharmaceuticals (USA) Inc., Nesher has considerable expertis e in niche therapies with development or products barriers, such as controlled release medications and DEA-controlled substances. ***

The release as fetched from its publisher. zyduslife.com ↗